Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
781-800 of 1,743 trials

Antiplatelet Therapy Reduction in High Bleeding Risk Patients

We are studying whether lowering the dose of antiplatelet medication helps patients with acute coronary syndrome who have had stents placed, while reducing the risk of bleeding. The trial compares different medication regimens to find the best balance between safety and effectiveness.

Acute Coronary Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Non-Small Cell Lung Cancer: Osimertinib with Datopotamab Deruxtecan

We are studying the safety and effectiveness of combining osimertinib with datopotamab deruxtecan in patients with advanced non-small cell lung cancer that has an EGFR mutation. This trial aims to see if the combination works better than osimertinib alone.

Non-Squamous Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Refractory Generalized Myasthenia Gravis: KYV-101 Therapy

We are studying a new CAR T-cell therapy for individuals with refractory generalized myasthenia gravis. The goal is to evaluate its safety and effectiveness in improving muscle strength.

Myasthenia GravisRefractory Generalized Myasthenia Gravis>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInfectious DiseasesNeurology

Stroke Treatment: Thrombolysis for Patients on Factor Xa Inhibitors

We are studying whether intravenous thrombolysis can improve recovery in stroke patients who have recently taken Factor Xa inhibitors. This trial compares the effects of this treatment to standard care options.

Acute Ischemic Stroke>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Mantle Cell Lymphoma: Zanubrutinib with Rituximab

We are comparing a new treatment combining Zanubrutinib and Rituximab to standard therapy for patients with untreated mantle cell lymphoma who cannot have a stem cell transplant. The goal is to see which treatment works better and is safer.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Pegozafermin for Metabolic Dysfunction-Associated Steatohepatitis (MASH)

We are studying whether pegozafermin can improve liver health in people with MASH and fibrosis compared to a placebo. This trial will help us understand its safety and effectiveness over time.

Nonalcoholic Fatty Liver Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyHepatology

Chemotherapy Dose Adjustment for DPD-Deficient Gastrointestinal Cancer Patients

We are studying how to safely adjust chemotherapy doses for patients with gastrointestinal cancers who lack a specific liver enzyme. This may help reduce severe side effects during treatment.

Gastrointestinal Cancer Patients Starting Chemotherapy>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Chronic Low Back Pain: Stem Cell Injection Study

We are investigating whether injecting stem cells into the spine can help reduce pain and improve function in people with chronic low back pain from degenerative disc disease. This trial is for those who haven't responded to traditional treatments.

Degenerative Disc Disease>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Metastatic Pancreatic Cancer: Dostarlimab with mFOLFIRINOX

We are studying a new treatment combining Dostarlimab, vitamin D3, and standard chemotherapy for patients with untreated metastatic pancreatic cancer. The goal is to see if this combination can effectively fight the cancer and assess its safety.

Metastatic Pancreatic Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Ketamine for Reducing Opioid Use in Severe Trauma

We are studying whether low doses of ketamine can help reduce the need for morphine in patients with severe trauma. This trial will also look at pain control and any side effects during treatment.

Traumatism>2 yearsConfirmation phase (III)Investigational MedicinesInternal MedicineOtolaryngologyPsychiatry

Melanoma Treatment: Comparing Pembrolizumab Formulations

We are studying whether a new formulation of Pembrolizumab is similar to existing treatments for patients with completely removed stage IIB, IIC, and III melanoma. This research aims to ensure effective adjuvant therapy options for these patients.

Stage IIB, IIC, and III Melanoma>2 yearsSafety phase (I)DermatologyOncology

Mucopolysaccharidosis IIIA: Gene Therapy Study

We are testing a new gene therapy called UX111 for individuals with Mucopolysaccharidosis IIIA. The goal is to see if it is safe and effective in treating this condition.

Mucopolysaccharidosis III>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurologyPediatrics

Non-Functioning Pituitary Adenomas: Cabergoline Treatment

We are studying the effects of cabergoline on non-functioning pituitary adenomas. This trial aims to see if this medication can improve treatment outcomes for patients.

Non-functioning Pituitary Adenoma>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOncology

Bone Health: Alendronate Discontinuation Study

We are investigating the effects of stopping alendronate on fracture risk in patients with osteoporosis. The study also looks at whether specific health factors can predict bone loss after discontinuation.

Osteoporosis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineOtolaryngology

Venous Malformations: Enalapril Study

We are testing the medication enalapril in adults with painful venous malformations to see if it helps reduce pain and improve quality of life. We will also look at any changes in the size of the malformations.

Venous Malformation>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

Stage IV Non-Small Cell Lung Cancer: Immunotherapy and Radiotherapy Study

We are exploring whether combining immunotherapy with extensive radiotherapy is safe and effective for patients with stage IV non-small cell lung cancer. This study will help us understand the treatment's impact on health and quality of life.

Non-small Cell Lung Cancer (Stage IV)>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Corneal Endothelial Transplantation: NSAIDs vs. Steroids

We are comparing two medication regimens to see if adding NSAIDs helps reduce inflammation and cystoid macular edema after corneal endothelial transplantation. This study is for patients undergoing this specific eye surgery.

Fuchs Dystrophy>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesOphthalmology

Breast Cancer: Personalized Treatment with Capivasertib

We are studying a new treatment combining capivasertib with letrozole for women with hormone receptor positive breast cancer. This trial aims to see if this approach improves survival compared to standard treatment.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Cardiac Arrest: Amiodarone Treatment Study

We are investigating whether giving amiodarone to critically ill patients after a cardiac arrest can lower the risk of death and serious heart rhythm problems. This study focuses on patients with a shockable rhythm and aims to improve their outcomes.

Out-of-Hospital Cardiac Arrest>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Metastatic Squamous Non-Small Cell Lung Cancer: Pembrolizumab Study

We are studying the effects of pembrolizumab alone or with MK-2870 in patients with metastatic squamous non-small cell lung cancer. The goal is to see which treatment may improve survival and quality of life.

Squamous Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology